
New approaches for treating all schizophrenia symptoms by modulating dopamine and glutamate in non-traditional ways.

New approaches for treating all schizophrenia symptoms by modulating dopamine and glutamate in non-traditional ways.

Data for generalized anxiety disorders and cannabis use is scarce, but pharmacists can help educate patients on potential benefits and risks of cannabis usage.

Expert perspective on current research, treatment approaches, and clinical considerations for pharmacologic management of borderline personality disorder

Potential adjunctive and novel treatment options based on a patient's specific symptoms and clinical factors are being explored to treat treatment-resistant schizophrenia

The abstracts will be presented at the American College of Cardiology Conference from April 6 to April 8, 2024, in Atlanta, Georgia.

Developments in glycine transporter type 1 inhibitors, D-amino acid oxidase inhibitors, and phosphodiesterase inhibitors are pushing schizophrenia research forward.

The results further confirm earlier findings from the EMPA-KIDNEY trial.

Although the number of clinical trials has quadrupled, the number of FDA approvals remains stable over a 10-year period, highlighting workforce challenges in clinical research.

These FDA-approved therapies are used to treat lymphoma after 2 or more lines of therapy and represent significant advancements in the treatment of lymphoma.

FDA-approved BiTE therapies for relapsed/refractory multiple myeloma show promising response rates, offering off-the-shelf alternatives to CAR T therapy.

Despite being a Schedule I drug, cannabis is increasingly used in oncology for symptom management, although data remains limited.

Lisa Janssen Carlson, PharmD, BCOP, discusses some background and history of regulations for the conduct of clinical trials.

Pharmacy Times will be at the American Association of Psychiatric Pharmacists (AAPP) Annual Meeting in Orlando, Florida from April 7 to April 10, 2024.

Precision medicine revolutionized NSCLC treatment, targeting specific mutations like KRAS G12C with therapies such as adagrasib to improve patient outcomes.

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

Pharmacists play a pivotal role working alongside the DEA and OIG in enforcing and preventing drug diversion nationally.

An FDA executive discusses the Surgeon General’s recommendations for promoting mental health and wellbeing for employees in the workplace.

A pharmacist discusses the impact of comprehensive weight management with a shared decision making approach.

These therapies can improve treatment adherence for patients, especially for those with a history of poor or uncertain adherence.

Studies have shown that the presence of advanced pharmacy technicians in a pharmacy has a positive predictive validity to increased monthly immunizations.

Food pharmacies, in particular, can be a great opportunity for pharmacists to collaborate with other providers, improve access to nutritious foods, and find unique opportunities to counsel patients.

Shared decision making with patients is a key component of RSV vaccination, which can bring challenges and opportunities.

In addition to improved efficacy, newer generations of anti-obesity medications have significantly improved safety concerns.

Sa'ed Al-Olimat, PharmD, also discussed the potentially groundbreaking shift for MDMA expected later in 2024.

Pharmacogenomics could help streamline prescribing and dosing for psychiatric medications, avoiding the trial-and-error process common with these medications.

Pharmacists can educate patients on current clinical evidence of cannabis’s therapeutic benefit, as well as cannabis’s complexities, risks, and potential adverse effects.

Expert Jennifer Clements discussed the evolving landscape of weight management medications, clinical considerations, and obstacles to use.

As more states have legalized cannabis use—both medicinal and recreational—Sera said pharmacists’ roles in counseling will become even more important.

Holloway discusses gender-affirming care, the challenging current legal landscape, and in particular how pharmacists can best serve their patients who are transgender or gender diverse.

Identifying the best uses for these tools, whether in patient education, data collection, improving efficiencies, or other uses, could significantly improve the future of pharmacy.